Tackling Glaucoma from within the Brain: An Unfortunate Interplay of BDNF and TrkB
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
According to the neurotrophin deprivation hypothesis, diminished retrograde delivery of neurotrophic support during an early stage of glaucoma pathogenesis is one of the main triggers that induce retinal ganglion cell (RGC) degeneration. Therefore, interfering with neurotrophic signaling seems an attractive strategy to achieve neuroprotection. Indeed, exogenous neurotrophin administration to the eye has been shown to reduce loss of RGCs in animal models of glaucoma; however, the neuroprotective effect was mostly insufficient for sustained RGC survival. We hypothesized that treatment at the level of neurotrophin-releasing brain areas might be beneficial, as signaling pathways activated by target-derived neurotrophins are suggested to differ from pathways that are initiated at the soma membrane. In our study, first, the spatiotemporal course of RGC degeneration was characterized in mice subjected to optic nerve crush (ONC) or laser induced ocular hypertension (OHT). Subsequently, the well-known neurotrophin brain-derived neurotrophic factor (BDNF) was chosen as the lead molecule, and the levels of BDNF and its high-affinity receptor, tropomyosin receptor kinase B (TrkB), were examined in the mouse retina and superior colliculus (SC) upon ONC and OHT. Both models differentially influenced BDNF and TrkB levels. Next, we aimed for RGC protection through viral vector-mediated upregulation of collicular BDNF, thought to boost the retrograde neurotrophin delivery. Although the previously reported temporary neuroprotective effect of intravitreally delivered recombinant BDNF was confirmed, viral vector-induced BDNF overexpression in the SC did not result in protection of the RGCs in the glaucoma models used. These findings most likely relate to decreased neurotrophin responsiveness upon vector-mediated BDNF overexpression. Our results highlight important insights concerning the complexity of neurotrophic factor treatments that should surely be considered in future neuroprotective strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The yin and yang of neurotrophin action
Lu, B., Pang, P. T., & Woo, N. H. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1726 · Cited by 1,356
Mansour-Robaey, S., Clarke, D. B., Wang, Y. C., Bray, G. M., & Aguayo, A. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.5.1632 · Cited by 731
Nadal-Nicola´s, F. M., Jime´nez-Lo´pez, M., Sobrado-Calvo, P., Nieto-Lo´pez, L., Ca´novas-Marti´nez, I., Salinas-Navarro, M., Vidal-Sanz, M., & Agudo, M. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-3267 · Cited by 541 · cited 2×
“RGC loss elicited by ONC appeared diffuse and affected the whole retina, without any evidence of a sectorial pattern, which is in line with literature[28, 49].”
Self-citationAschauer, D. F., Kreuz, S., & Rumpel, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076310 · Cited by 522 · cited 1×
“Based on the fact that the applicability of different viral vector systems depends on the experimental setup, tissue, and species[46, 47], we first defined the optimal vector system for local delivery to the mouse SC [48].”
Depolarization and cAMP Elevation Rapidly Recruit TrkB to the Plasma Membrane of CNS Neurons
Meyer-Franke, A., Wilkinson, G. A., Kruttgen, A., Hu, M., Munro, E., Hanson, M. G., Reichardt, L. F., & Barres, B. A. (1998) · Neuron · doi:10.1016/s0896-6273(00)80586-3 · Cited by 516
New recombinant serotypes of AAV vectors
Gao, G., Vandenberghe, L., & Wilson, J. (2005) · Current Gene Therapy · doi:10.2174/1566523054065057 · Cited by 487
Harada, T., Harada, C., Kohsaka, S., Wada, E., Yoshida, K., Ohno, S., Mamada, H., Tanaka, K., Parada, L. F., & Wada, K. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-21-09228.2002 · Cited by 397
Comparative Analysis of Adeno-Associated Viral Vector Serotypes 1, 2, 5, 7, And 8 in Mouse Brain
Taymans, J.-M., Vandenberghe, L. H., Haute, C. V. D., Thiry, I., Deroose, C. M., Mortelmans, L., Wilson, J. M., Debyser, Z., & Baekelandt, V. (2007) · Human Gene Therapy · doi:10.1089/hum.2006.178 · Cited by 305 · cited 1×
“Based on the fact that the applicability of different viral vector systems depends on the experimental setup, tissue, and species[46, 47], we first defined the optimal vector system for local delivery to the mouse SC [48].”
Self-citationBaekelandt, V, Eggermont, K., Michiels, M., Nuttin, B., & Debyser, Z. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302094 · Cited by 153
Self-citationNovel adeno-associated viral vectors for retinal gene therapy.
Vandenberghe, L. H., & Auricchio, A. (2012) · Gene Therapy · doi:10.1038/gt.2011.151 · Cited by 131
Chen, H., & Weber, A. J. (2004) · Brain Research · doi:10.1016/j.brainres.2004.03.024 · Cited by 75 · cited 2×
“desensitization of the signal transduction pathways[7, 26, 72].”
Cited by
Glaucoma: the retina and beyond
Davis, B. M., Crawley, L., Pahlitzsch, M., Javaid, F., & Cordeiro, M. F. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1609-2 · Cited by 281
Osborne, A., Khatib, T. Z., Songra, L., Barber, A. C., Hall, K., Kong, G. Y. X., Widdowson, P. S., & Martin, K. R. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-1041-8 · Cited by 175
Dada, T., Mittal, D., Mohanty, K., Faiq, M. A., Bhat, M. A., Yadav, R. K., Sihota, R., Sidhu, T., Velpandian, T., Kalaivani, M., et al. (2018) · Journal of Glaucoma · doi:10.1097/ijg.0000000000001088 · Cited by 135
Neuroprotection in Glaucoma: Animal Models and Clinical Trials
Almasieh, M., & Levin, L. A. (2017) · Annual Review of Vision Science · doi:10.1146/annurev-vision-102016-061422 · Cited by 111
“It is unclear whether protection of the optic nerve itself will also prevent those secondary changes within the efferent neurons of the RGCs or whether both need to be protected separately (Dekeyster et al. 2015).”
The concept of gene therapy for glaucoma: the dream that has not come true yet
Sulak, R., Liu, X., & Smedowski, A. (2024) · Neural Regeneration Research · doi:10.4103/1673-5374.375319 · Cited by 40
“There have been several attempts to utilize the neurotrophic factors, mainly brain-derived neurotrophic factor (BDNF), which plays a key role in the survival, plasticity, and growth of neurons, including RGCs (Dekeyster et al., 2015; Kimura et al., 2016; Kuo and Liu, 2022).”
Metadata
- Authors
- Dekeyster, E., Geeraerts, E., Buyens, T., Van den Haute, C., Baekelandt, V., De Groef, L., Salinas-Navarro, M., & Moons, L.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-11-11
- Volume
- 10
- Issue
- 11
- Pages
- e0142067
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2180013487
- Cited by
- 49
- References
- 11
- FWCI
- 4.34
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.